NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...

International Childhood Cancer Day aims to spread awareness about childhood cancers. Childhood cancers (0-14 years of age) ...

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

The Da Vinci SP made its way to the operating room for doctors at Trident Medical Center. The robot that uses a single port, ...

The NHS says it already offers some CAR-T therapies and is consulting on "potential future treatments". Only this week, the National Institute for Health and Care Excellence has recommended the use of ...